Bradley Jenkins, MD
Family Medicine · North Little Rock, ARNPI 1568571438
Payments from drug & device makers
Across 470 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- GSK$951
- Pfizer$541
- Astellas Pharma US Inc$459
- Novo Nordisk$441
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,77399%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,170 |
| Amgen | 76 | $1,028 |
| GSK | 65 | $951 |
| Pfizer | 52 | $541 |
| Astellas Pharma US Inc | 27 | $459 |
| Novo Nordisk | 28 | $441 |
| AstraZeneca | 20 | $363 |
| Johnson & Johnson | 16 | $212 |
| Merck | 14 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $193 |
| Novartis | 12 | $186 |
| Biohaven Pharmaceuticals, Inc. | 10 | $143 |
| Supernus Pharmaceuticals, Inc. | 5 | $109 |
| Lilly USA, LLC | 7 | $107 |
| Boehringer Ingelheim | 5 | $105 |
| Bayer | 7 | $102 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Dexcom, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Medtronic | 1 | $26 |
| Antares Pharma, Inc. | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Vapotherm Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$6,843 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $177,821 |
| EliquisApixaban | 179 | $166,027 |
| JardianceEmpagliflozin | 179 | $159,623 |
| OzempicSemaglutide | 90 | $110,994 |
| JanumetSitagliptin Phos/Metformin Hcl | 100 | $88,691 |
| Taltz AutoinjectorIxekizumab | 13 | $87,397 |
| XareltoRivaroxaban | 68 | $54,452 |
| JanuviaSitagliptin Phosphate | 66 | $52,488 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $39,097 |
| TradjentaLinagliptin | 47 | $36,660 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $36,625 |
| NucyntaTapentadol Hcl | 25 | $35,488 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $35,030 |
| Repatha SureclickEvolocumab | 38 | $32,962 |
| MyrbetriqMirabegron | 49 | $26,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $105 | $203,273241 claims |
| Lilly USA, LLCMounjaro | $107 | $177,821147 claims |
| PfizerEliquis | $541 | $166,027179 claims |
| MerckJanumet, Januvia, Belsomra | $206 | $146,878179 claims |
| Novo NordiskOzempic | $441 | $110,99490 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $951 | $61,681100 claims |
| Johnson & JohnsonXarelto | $212 | $54,45268 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $363 | $46,25879 claims |
| AbbVieLinzess, Savella | $1,170 | $30,22451 claims |
| Astellas Pharma US IncMyrbetriq | $459 | $26,80349 claims |
| BayerKerendia | $102 | $8,33813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in North Little Rock
- Michael BerryNorth Little Rock$18K
- Richard HeckNorth Little Rock$13K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.